Clinical Trials at Tays Cancer Centre

Contact Information: FONK(at)pshp.fi
(Please replace (at) with @-symbol when sending e-mail.)

Kliiniset tutkimukset -avoinna = Open for inclusion
Kliiniset tutkimukset - ei uusia potilaita = Closed for inclusion

Cancer type

Title of the study

Acute leukemia (AML) Kliiniset tutkimukset -avoinna

R18034M

CPKC412A2408: Rimpiläinen

An open-labeled, multi–center, Phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) who are eligible for “7+3” or “5+2” chemotherapy.

Acute leukemia (AML)

Kliiniset tutkimukset -avoinna

R17115M

MIRROS: Rimpiläinen

A multicenter, double-blind, randomized, placebo-controlled, phase III study of Idasanutlin, an mdm2 antagonist, with Cytarabine versus Cytarabine plus placebo in patients with relapsed or refractory acute myeloid leukemia (aml).

Acute leukemia (AML)

Kliiniset tutkimukset - ei uusia potilaita

R17112M

VIALE-A: Rimpiläinen

A randomized, double-blind, placebo controlled, phase III study of Venetoclax in combination with Azacitidine versus Azacitidine in treatment naïve subjects with acute myeloid leukemia who are ineligible for standard induction therapy.

Acute leukemia (ALL)

Kliiniset tutkimukset -avoinna

R09080

NOPHO: Rimpiläinen

Treatment protocol for children (1.0 - 17.9 years of age) and young adults (18-45 years of age) with acute lymphoblastic leukemia. Phase III trial.

Bladder cancer Kliiniset tutkimukset -avoinna

R18164M

KEYNOTE-676: Tammela

A phase III, randomized, comparator-controlled clinical trial to study the efficacy and safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer (HR NMIBC) that is persistent or recurrent following BCG induction.

Bladder cancer Kliiniset tutkimukset - ei uusia potilaita

R15126M

WO29636 /Imvigor: Tammela

A phase III, open-label, multicenter, randomized study of MPDL3280A (ANTI-PD‑L1 ANTIBODY) versus observation as adjuvant therapy in patients with PD‑L1-Selected, high-risk muscle-invasive bladder cancer after cystectomy

Breast cancer Kliiniset tutkimukset -avoinna

R16008M

BOLD: Kellokumpu-Lehtinen

A randomized phase III study comparing trastuzumab, pertuzumab,pertuzumab plus docetaxel followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2 positive breast cancer

Breast cancer Kliiniset tutkimukset - ei uusia potilaita

R14108M

13Y-MC-JBPL / MONARCH: Kellokumpu-Lehtinen

A randomized, double-blind, placebo-controlled, phase III study of fulvestrant with or without LY2835219, a CDK4/6 Inhibitor, for women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer

Breast cancer Kliiniset tutkimukset - ei uusia potilaita

R07195M

SOLD: Kellokumpu-Lehtinen 

A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single agent trastuzumab as adjuvant treatments for early breast cancer

Breast cancer Kliiniset tutkimukset - ei uusia potilaita

R17078M

MonarchE I3Y-MC-JPCF:  Kellokumpu-Lehtinen

A randomized, open-label, phase III study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone positive, human epidermal receptor 2 negative breast cancer

Breast cancer Kliiniset tutkimukset - ei uusia potilaita

R19038M

CLEEO11A2404: Tanner

An open-label, multicenter, phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor –positive (HR+) HER2 –negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.

Breast cancer,
HER2 neg
Kliiniset tutkimukset -avoinna

R19083M

1280.18: Tanner

An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally  advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts.

Breast cancer,
HER2 neg
Kliiniset tutkimukset - ei uusia potilaita

R14118M

M12-914/BROCADE/AbbVie Inc: Tanner

A randomized, double-blind, placebo-controlled, phase III study of fulvestrant with or without LY2835219, a CDK4/6 inhibitor, for women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer

Breast cancer,
HER2 neg
Kliiniset tutkimukset - ei uusia potilaita

R12043M

PERUSE: Tanner

A multicenter, open-label, single-arm study of pertuzumab in combination with trastutzumab and a taxane in first line treatment of patients with HER2-positive advanced (metastatic or locally recurrent) breast cancer.

Breast cancer, triple neg Kliiniset tutkimukset - ei uusia potilaita

R16048M

Impassion130: Tanner

A phase III, multicenter, randomized, placebocontrolled study of atezolizumab (anti−pd-l1antibody) in combination with nab-paclitaxel compared with placebo with nab-paclitaxel for patients with previously untreated metastatic triple-negative breast cancer

Breast cancer, triple neg Kliiniset tutkimukset - ei uusia potilaita

R18072M

MO39193/Impassion 132/Tanner

A phase III randomized, placebocontrolled multi-center study of the efficacy and safety of atezolizumab in combination with chemotherapy for patients with early relapsed triple-negative breast cancer.

Breast cancer, triple neg Kliiniset tutkimukset - ei uusia potilaita

MK-3475-173 (KEYNOTE 173): Tanner

A phase 1b study to evaluate safety and clinical activity of pembrolizumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) –

Cancer of Unknown Primary Kliiniset tutkimukset -avoinna

R18017M

CUPISCO MX39795: Tanner Minna

A phase II, randomized, activecontrolled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy.  

Carcinoma of the esophagus Kliiniset tutkimukset - ei uusia potilaita

R16016M

Mk-3475-181: Salminen

A phase III randomized open-label study of single agent pembrolizumab vs physician`s choice of single agent docetaxel, paclitaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus that have progressed after first-line standard therapy MK-347-181

CLL Kliiniset tutkimukset - ei uusia potilaita

R18015M

HO141 CLL: Luopajärvi

A prospective,  multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.

CLL Kliiniset tutkimukset - ei uusia potilaita

R17047M

CLL13 GAIA: Luopajärvi

A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.

Cholangiocarcinoma Kliiniset tutkimukset -avoinna

R19065M

INCYTE FIGHT-302: Österlund

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

Colorectal cancer Kliiniset tutkimukset - ei uusia potilaita

R12116M

RAXO: Österlund

A population-based prospective study to evaluate clinical behaviour, resectability and survival in metastatic colorectal cancer patients in Finland.

Colorectal cancer Kliiniset tutkimukset - ei uusia potilaita

R16017M

MK-3475-177: Salminen

A phase III study of pembrolizumab (MK-3475) vs chemotheraby in microsatellite instability-high (MSI-H) or mismatch repair deficient (DMMR) stage IV colorectal carcinoma (MK-347-177)

Colorectal cancer Kliiniset tutkimukset -avoinna

R12117M

AXOAXI: Salminen

Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer

Colorectal cancer Kliiniset tutkimukset - ei uusia potilaita

R16138M

NORDIC-9: Salminen

Full dose monotherapy S-1 (followed by irinotecan) compared to reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer. Phase II study.

Endometrial cancer Kliiniset tutkimukset - ei uusia potilaita

R16094M

FANDANGO : Mäenpää

First line combination chemotherapy with Nintedanib / placebo for patients with advanced or recurrent endometrial cancer, phase II trial

Endometrial cancer Kliiniset tutkimukset - ei uusia potilaita

R16187M

PALEO: Auranen

A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus placebo in combination with Letrozole for patients with estrogen receptor positive advanced or recurrent endometrial cancer

Endometrial cancer Kliiniset tutkimukset -avoinna

EN2-DGCG: Vuento

Chemotherapy or observation in stage I-II intermediate or high risk endometrial cancer

Gastrointestinal tract carcinoma Kliiniset tutkimukset -avoinna

R14050M

FluHeart: Salminen

Effects of S-1 and capecitabine in combination with oxaliplatin on the coronary artery blood flow in patients with metastatic gastrointestinal tract adenocarcinoma, phase II study.

GIST Kliiniset tutkimukset -avoinna

R15127M

GIST SSGXXII: Sunela

Three versus five years of adjuvant Imatinib as treatment of patients with operable GIST with a high risk for recurrence: a randomised phase III multicenter study by the Scandinavian Sarcoma Group

Head and neck carcinoma Kliiniset tutkimukset - ei uusia potilaita

MK-3475-048: Kellokumpu-Lehtinen

A phase III clinical trial of Pembrolizumab (MK-3475) in first line treatment of recurrent/ metastatic head and neck squamous cell carcinoma

Lymphoma Kliiniset tutkimukset -avoinna

R17145M

BIO-CHIC/ Sunela Kaisa:

Biomarker driven and dose intensified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B-cell lymphoma (NLG-LBC-06)

Lymphoma Kliiniset tutkimukset -avoinna

CHIC/NLG: Lehtinen

Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk (aaIPI>2) Diffuse Large B-cell Lymphoma

Lymphoma Kliiniset tutkimukset -avoinna

R18211M

SAKK/ Kaisa Sunela:

Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial.

Lymphoma
Diffuse Large B-cell Lymphoma
Kliiniset tutkimukset -avoinna

R16108M

MOR00208/B-MIND: Lehtinen

A phase II/III, randomised, multicentre study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem-cell transplantation (ASCT) – B-MIND

Lymphoma
Non-Hodgkin
Kliiniset tutkimukset -avoinna

R17032M

CHRONOS-4: Sunela

A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor Copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL)

Lymphoma
Non-Hodgkin
Kliiniset tutkimukset - ei uusia potilaita

R14154M

BAY 80-6946: Sunela

Open-label, uncontrolled phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive non-Hodgkin's lymphomas

Melanoma Kliiniset tutkimukset - ei uusia potilaita

R13091M

Ca209-067: Skyttä

A Phase 3, randomized, double-blind study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in subjects with previously untreated unresectable or metastatic melanoma.

Melanoma Kliiniset tutkimukset - ei uusia potilaita

R15089M

CA209-238: Skyttä

A phase III, randomized, double-blind study of adjuvant immunotherapy with Nivolumab versus Ipilibumab after complete resection of st IIIb/c or st IV melanoma in subjects who are at high risk for recurrence

Melanoma Kliiniset tutkimukset - ei uusia potilaita

R161334

MK3475-054 (KEYNOTE-054): Skyttä

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody MK-3475 versus placebo after complete resection of high-risk stage III melanoma: A randomized, double-blind phase 3 trial of the EORTC Melanoma Group

Melanoma Kliiniset tutkimukset -avoinna

R18084M

Melanoma / CA224-047: Skyttä

A randomized, double-blind phase II–III study of BMS-986016 combined with Nivolumab versus Nivolumab in participants with previously untreated metastatic or unresectable melanoma.

Melanoma Kliiniset tutkimukset - ei uusia potilaita

R18130M

Combi-APlus/ Leena Tiainen

Open-label, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate the impact on pyrexia related outcomes of an adapted pyrexia AE-management algorithm (Plus).

Myeloma Kliiniset tutkimukset -avoinna

R18039M

Myeloma: IRd NMSG 23/15: Sankelo

A prospective phase 2 study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients.

Myeloma Kliiniset tutkimukset -avoinna

KeD: Sankelo

Phase 2 study of carfilzomib + elotuzumab +dexamethasone for relapsed or progressed multiple myeloma after 1-3 prior treatment lines.

Ovarian cancer Kliiniset tutkimukset - ei uusia potilaita

R17105M

IMagyn050, Johanna Mäenpää

A phase III, multicenter, randomized, study of Atezolizumab versus Plasebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab to patients with newly-diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer

Ovarian cancer Kliiniset tutkimukset - ei uusia potilaita

R16061M

AVANOVA: Mäenpää

Niraparib vs. niraparib-bevacizumab combination in women with  platinum-sensitive epithelial ovarian, fallopian tube or peritoneal cancer. Phase II trial.

Ovarian cancer Kliiniset tutkimukset -avoinna

R18152M

Tesaro FIRST: Mäenpää

A randomized, double-blind, phase 3 comparison of platinum-based therapy with TSR-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of stage III or IV nonmucinous epithelial ovarian cancer.

Ovarian cancer Kliiniset tutkimukset - ei uusia potilaita

R16104M

Tesaro PRIMA: Mäenpää

A phase 3, randomized, double-blind, placebo-controlled, multicenter study of Niraparib maintenance treatment in patients with HRD-positive advanced ovarian cancer following response on front-line platinum-based chemotherapy.

Ovarian cancer Kliiniset tutkimukset - ei uusia potilaita

EWOC-1: Auranen

Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer

Ovarian cancer Kliiniset tutkimukset - ei uusia potilaita

R16020M

MK-3475-100 (KEYNOTE-100): Mäenpää

Pembrolizumab in patients with recurrent ovarian cancer

Ovarian cancer Kliiniset tutkimukset - ei uusia potilaita

R16064M

PAOLA: Mäenpää

Platinum, avastin and olaparib in first line treatment of patients with advanced ovarian/fallopian tube/peritoneal cancer. Phase III trial.

Ovarian cancer Kliiniset tutkimukset - ei uusia potilaita

R11119M

INOVATYON: Mäenpää

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum. Phase III trial. 

Ovarian cancer Kliiniset tutkimukset - ei uusia potilaita

R18078M

NSGO-UMB1 ENGOT-OV30 / UMBRELLA: Mäenpää Johanna

A phase II umbrella trial in patients with relapsed ovarian cancer.

Ovarian cancer Kliiniset tutkimukset - ei uusia potilaita

R18189M

OPINION: Mäenpää Johanna

A phase IIIb, single-arm, ppen-label multicentre study of Olaparib maintenance monotherapy in platinum sensitive relapsed non- germline BRCA mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy

Pancreatic adenocarcinoma Kliiniset tutkimukset - ei uusia potilaita

R14070M

APACT: Salminen

A phase III, multicenter, open-label randomized study of NAB-PACLITAXEL plus GEMCITABINE alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma

Pancreatic adenocarcinoma Kliiniset tutkimukset -avoinna

R18120M

GRASPANC: Österlund

A Randomized,  Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma.

Prostate cancer Kliiniset tutkimukset -avoinna

R19062M

Talapro-2: Tammela

A Phase 3 randomized double-blind placebo-controlled study of talazoparib in combination with enzalutamide in men with metastatic castration resistant prostate cancer.  

Prostate cancer Kliiniset tutkimukset - ei uusia potilaita

R17073M

M-HERO: Tammela

A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer.

Prostate cancer Kliiniset tutkimukset - ei uusia potilaita

R18020M

Astellas: Tammela

A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study.

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R16033H

9785-CL-0403 Arches : Tammela

A multinational, phase III, randomized, double-blind, placebo-controlled efficacy and safety study of Enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC), protocol number 9785-CL-0335

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R14009

ESKO: Reinikainen

Radiotherapy in prostate cancer

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R16118M

ODX-003: Tammela

A randomised, double-blind, dose finding, repeat dose phase II multicentre study of ODX for the treatment of patients with castration-resistant prostate cancer (CRPC) and skeletal metastases

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R14041M

ARAMIS: Tammela

A multinational, randomized, double-blind, placebo-controlled, phase III efficacy and safety study of ODM-201  in men with high-risk non-metastatic castration-resistant prostate cancer

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R15062M

MDV3100-13 /Embark: Tammela

A phase III, randomized, efficacy and safety study of Enzalutamide plus Leuprolide, Enzalutamide monotherapy, and placebo plus Leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R16201M

ARASENS: Tammela

A randomized, double-blind, placebo-controlled phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and Docetaxel in patients with metastatic hormone-sensitive prostate cancer

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R13101M

MDV3100-14 /PROSPER: Tammela

A multinational, phase III, randomized, double-blind, placebo-controlled, efficacy and safety study of Enzalutamide patients with nonmetastatic castration-resistant prostate cancer

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R13119M

MDV3100-10/PLATO: Tammela

A phase IV, randomized, double-blind, placebo-controlled study of continued Enzalutamide treatment beyond progression in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R14049M

Bayer 15396: Paunu

A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with Abiraterone acetate and Prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R16072M

KEYNOTE-199: Kellokumpu-Lehtinen

Phase II trial of Pembrolizumab (MK-3475) in subjects with metastatic castration-resistant prostate cancer (mCRPC) previously treated with chemotherapy

Prostate cancer

Kliiniset tutkimukset - ei uusia potilaita

R06170M

AdRad: Kellokumpu-Lehtinen

A randomized adjuvant phase III trial of six cycles of Docetaxel+hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiotherapy (SPCG-13)

Renal Cell Carcinoma Kliiniset tutkimukset - ei uusia potilaita

R15010M

Ca209-214:Kellokumpu-Lehtinen

A Phase 3, randomized, open-label study of Nivolumab combined with Ipilimumab versus Sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma.

Renal Cell Carcinoma

  Kliiniset tutkimukset - ei uusia potilaita

R17092M

KEYNOTE-564: Sillanpää

A phase III, randomized, double-blind, placebo-controlled clinical trial of Pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy

Renal Cell Carcinoma

R17119M

R17119M

Eisai: Sunela

A Randomized, double-blind, phase 2 trial to assess safety and efficacy of Lenvatinib at two different starting doses (18 mg vs. 14 mg QD) in combination with Everolimus (5 mg QD) in renal cell carcinoma following one prior VEGF-targeted treatment

Solid tumors Kliiniset tutkimukset -avoinna

R17127M

M15-891/ Tanner Minna:

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, as Monotherapy and in Combination with Another Anti-Cancer Therapy in Subjects with Advanced Solid Tumors.

Urothelial carcinoma Kliiniset tutkimukset -avoinna

R18095M

BAY 1163877: Kellokumpu-Lehtinen & Sormunen

A randomized, open label, multicenter Phase II-III study to evaluate the efficacy and safety of rogaratinib (BAY 163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinumcontaining chemotherapy.

Urothelial carcinoma Kliiniset tutkimukset - ei uusia potilaita

R15126M

WO29636: Tammela

A phase III, open-label, multicenter, randomized study of atetzolizumab (ANTIPD-L1 antibody) versus observation as adjuvant therapy in patients with high-risk muscle-invasive urothelial carsinoma after surgigal resection.

Kliiniset tutkimukset -avoinna

R18212M

Bayer 16996: Tanner

A Phase 4 long-term follow-up study to define the safety profile  of radium-223 dichloride.